BridgeBio Expands U.S. Access to Rare Disease Medicines
PALO ALTO, Calif., August 31, 2026 BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on medicines for...
ATTR-CM
Advertisement
BridgeBio Pharma Reports New Acoramidis Data at ESC 2026
PALO ALTO, Calif., August 30, 2026 BridgeBio Pharma, Inc. presented new data from the Phase 3 ATTRibute-CM study of...
Alnylam Presents ATTR-CM Data at ESC Congress 2026
Cambridge, Mass. – August 30, 2026 Alnylam Pharmaceuticals announced new clinical data at the European Society of Cardiology (ESC)...
BridgeBio Starts Phase 3b/4 ASCEND-ATTR Acoramidis Study
PALO ALTO, Calif., Aug. 26, 2026 BridgeBio Pharma, Inc. has announced that the first participant has been dosed in...
ArkBio Completes Phase I Dosing of AK0406 Influenza Drug
SHANGHAI, July 23, 2026 ArkBio has successfully completed dosing across all cohorts in its Australian Phase I clinical trial...
Advertisements
Lundbeck Wins FDA Fast Track for Lu AH69593 in Narcolepsy
VALBY, Denmark, July 23, 2026 Lundbeck has received U.S. Food and Drug Administration (FDA) Fast Track designation for Lu...
Royalty Pharma Acquires Cliramitug Royalty Rights from Neurimmune
NEW YORK, July 22, 2026 Royalty Pharma plc has announced the acquisition of a portion of Neurimmune’s royalty interest...
AstraZeneca Reports Wainua Phase III ATTR-CM Trial Results
CAMBRIDGE, United Kingdom, July 9, 2026 AstraZeneca and Ionis Pharmaceuticals have announced results from the Phase III CARDIO-TTRansform trial...
BridgeBio Reports Kidney Benefits With Attruby in ATTR-CM
PALO ALTO, Calif., July 2, 2026 BridgeBio Pharma, Inc. announced new post-hoc analyses published in Circulation: Heart Failure showing...
Advertisement
